Valneva's Shigella Vaccine Hits Phase 2 Endpoints in Infant and Adult Trials
VALN sits 22% above its 52-week low of $4.75 on light trading volume (0.1× avg).
Summary
Valneva reported positive Phase 2 data for Shigella4V2, its tetravalent bioconjugate shigellosis candidate, from two trials: an infant study in Kenya and an adult human challenge study in the US. The adult CHIM trial met its primary endpoint, showing a statistically significant reduction in S. sonnei shigellosis versus placebo; the infant trial showed a favorable safety profile and significant antibody titer increases across all four targeted serotypes, though the company flagged a need for dose and schedule optimization. LimmaTech sponsored both trials and the Gates Foundation funded the infant study. Valneva is now reviewing the full dataset to decide next development steps for what it calls the most clinically advanced tetravalent Shigella candidate. The readout gives the company a credible pipeline asset beyond IXCHIQ, whose UK authorization was revoked in October, and shares were up 5.26% at $5.80 on the news. Nine-month 2026 results are scheduled for November 24.
At the time of this announcement, VALN was trading at $5.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $530.3M. The 52-week trading range was $4.75 to $12.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.